Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

TGF-beta Gene Expression Signature in Cancer Prognosis

Posted Jun 30 2008 5:00pm

Description of Invention:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, and it is very heterogeneous in terms of its clinical presentation as well as genomic and transcriptomic patterns. This heterogeneity and the lack of appropriate biomarkers have hampered patient prognosis and treatment stratification.

Available for licensing is a novel temporal TGF-beta gene expression signature that predicts HCC patient clinical outcomes. Patients with tumors expressing late TGF-beta responsive genes had a malignant prognosis and an invasive tumor phenotype as evaluated by decreased survival time, increased tumor recurrence, and vascular invasion rate. Additionally, this signature may also be able to prognose other cancers, including lung cancer.

Applications:
  • Method to diagnose cancer
  • Method to monitor cancer progression and aid clinicians to choose appropriate therapies
  • Commercial kits to prognose cancer


Advantages:
Early diagnostic tool to stratify HCC patients to chose more effective treatment.

Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Snorri S Thorgeirsson (NCI)
Cedric Coulouarn (NCI)


Relevant Publication:
  1. Coulouaran C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008 Jun;47(6):2059-2067. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute, Center for Cancer Research, Laboratory of Experimental Carcinogenesis is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a novel temporal TGF-beta gene expression signature that predicts HCC patient clinical outcomes. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Diagnostics
Miscellaneous



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 1710

Updated: 07/2008

Post a comment
Write a comment: